Five Under 5: Top Oncology Videos for the Week of 2/2

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Benjamin P. Levy, MD, clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor of oncology at Johns Hopkins University School of Medicine, details the current clinical and developmental statuses of several antibody-drug conjugates in non–small cell lung cancer.

C. Ola Landgren, MD, PhD, professor of medicine and chief of the Division of Myeloma in the Department of Medicine at the University of Miami, Miller School of Medicine; director of Sylvester Myeloma Institute; co-leader of the Translational and Clinical Oncology Program and Paul J. DiMare Endowed Chair in immunotherapy at Sylvester Comprehensive Cancer Center, shed light on progress made in the realm of multiple myeloma. He highlighted changes to the paradigm during the 2024 ASH Annual Meeting.

Aditya Bardia, MD, MPH, FASCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center, explained the significance of the FDA approval of datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for the treatment of patients with pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

Pooja Phull, MD, hematologist/oncologist at John Theurer Cancer Center, Hackensack University Medical Center, details the differences between retrospective real-world and clinical trial data for ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma) in patients with relapsed/refractory multiple myeloma.

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine in the Division of Hematology and Oncology at Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, spotlights the efficacy of tazemetostat (Tazverik) vs placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) in patients with relapsed/refractory follicular lymphoma (FL), according to data from the phase 3 SYMPHONY-1 study (NCT04224493) leukemia.